Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Place for Surgery and Poor Prognosis

July 18th 2019

Differentiating Among the Types of Surgery

July 18th 2019

Surgery Options in Locally Advanced Gastric Cancer

July 18th 2019

Trastuzumab in HER2-Positive Gastroesophageal Cancer

July 18th 2019

First-Line Therapy in HER2-Negative Gastric Cancer

July 18th 2019

Treatment in HER2-Positive Disease and Dosing Preferences

July 18th 2019

Factors Determining Initial Treatment Approach for Gastric Cancer

July 18th 2019

Molecular Testing Used for Gastric Cancer

July 18th 2019

Genetic Risk, Screening, and Diagnosis for Gastric Cancer

July 18th 2019

Introduction and Global Trends of Gastric Cancer

July 18th 2019

NTRK Gene Fusions: Finding the "Golden Ticket" in Oncology

July 18th 2019

During an OncologyLive Peer Exchange, the panelists discuss some of the challenges they face when conducting molecular testing, including determining which patients to test, when to test, and how to test to ensure that no golden tickets, such as NTRK gene fusions, are missed. They also discuss the data surrounding TRK inhibitors and their experiences using these agents.

Dr. Llovet on REACH Trials With Ramucirumab in HCC

July 17th 2019

Josep M. Llovet, MD, PhD, discusses the REACH and REACH-2 trials, which examined ramucirumab versus placebo in sorafenib-intolerant patients with hepatocellular carcinoma and elevated baseline alpha fetoprotein.

Triplet Targeted Therapy May Signal a New Standard in Metastatic CRC

July 17th 2019

Now, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic colorectal cancer.

Dr. Bekaii-Saab on POLO Trial Results in Pancreatic Cancer

July 17th 2019

Tanios Bekaii-Saab, MD, FACP, discusses the clinical implications of the results of the phase III POLO trial in metastatic pancreatic cancer.

Dr. Manji on Predictive or Prognostic Biomarkers in GI Cancers

July 15th 2019

Gulam A. Manji, MD, PhD, discusses the role of finding biomarkers in patients with gastrointestinal cancers.

Regorafenib vs TAS-102 Salvage Therapy

July 15th 2019

Promising Novel Agents and Treatments

July 15th 2019

Ongoing Treatment & Approach Advancements in mCRC

July 15th 2019

Combination Therapy Updates from ASCO 2019

July 15th 2019

Later-Line Therapy Innovations in MCRC

July 15th 2019